Join the Oncology Voice Network. Join for Free
Bringing the Real Patient Voice to Oncology Decisions

Bringing the Real Patient Voice to Oncology Decisions


Share This Article


Who truly speaks for the patient when they’re not there to speak for themselves?

In this eye-opening episode of Oncology Voice Network, host Dr. Kirk Shepard is joined by Elizabeth Franklin, Head of US Public Affairs and Patient Advocacy for Oncology at Sanofi. Drawing on a career spanning frontline social work, policy, nonprofit advocacy, and industry leadership, Elizabeth Franklin reveals the real reasons the “patient voice” often gets lost when critical decisions are made in cancer care. Go beyond surface-level buzzwords as they unpack where patient advocacy can break through organizational resistance, how early decisions in drug development either open doors or shut them, and why it’s not enough to listen—true impact requires action and systemic redesign. Discover the micro and macro shifts the industry can no longer afford to delay, and what it actually takes to carry real patient insight into rooms of power.

If you care about moving oncology forward, don’t miss this powerful conversation. Tune in now.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN